ABSTRACT
Treatment for chronic hepatitis C virus (HCV) infection is evolving rapidly. The approval in 2013 of two new directacting antivirals—sofosbuvir (a polymerase inhibitor) and simeprevir (a second-generation protease inhibitor)— opens the door for an all-oral regimen, potentially avoiding interferon and its harsh side effects. Other direct-acting antivirals are under development.
- © 2014 The Cleveland Clinic Foundation. All Rights Reserved.